nyra health, a Vienna-based digital health company focused on AI-driven neurological therapy, has secured €20 million in Series A funding to accelerate international expansion and further develop its multimodal neurotherapy platform.
The round was led by Armira Growth, with renewed participation from Wellington Partners, Crane Venture Partners, which oversees MassMutual Ventures’ investments, and EVER Pharma. The capital will support product development, geographic expansion across the DACH region and the United States, and the continued advancement of its AI-based rehabilitation infrastructure.
What The Company Does
nyra health develops an AI-powered platform designed to support neurological rehabilitation across the full patient care journey, from inpatient therapy to long-term outpatient and home-based treatment. Its core product, the MDR Class IIa-certified medical device myReha, enables patients to train speech, cognition, fine motor skills, and daily functional abilities through adaptive digital therapy supported by real-time feedback.
The platform uses multimodal AI models to analyze performance metrics such as speech patterns, reaction times, error profiles, and training dynamics. Based on this data, therapy programmes automatically adjust to a patient’s progress, fatigue levels, and individual rehabilitation needs. Specialized speech models assess pronunciation, word retrieval, syntax, and semantic structure, enabling more granular therapy personalisation than traditional digital rehabilitation tools.
Alongside myReha, the company offers nyra insights, a clinical management system that allows therapists and specialists to monitor patient progress, therapy intensity, and outcome trends in real time. The system also supports automated documentation and programme adjustments, while an AI-supported content studio dynamically generates personalised therapy exercises based on individual patient data.
Advertisement
Market Context / Industry Background
Neurological disorders such as stroke, traumatic brain injury, and dementia represent a significant and growing healthcare burden, particularly in aging populations. In Germany alone, neurological conditions generate tens of billions of euros in annual costs, largely due to gaps in post-discharge care and insufficient long-term therapy intensity.
Traditional rehabilitation pathways often decline in frequency after hospital discharge, leading to fragmented follow-up care and suboptimal recovery outcomes. Digital neurorehabilitation platforms are increasingly being adopted to address these structural inefficiencies by enabling continuous, data-driven therapy outside clinical settings while reducing pressure on limited therapist resources.
The integration of reimbursable digital therapeutics into standard care models is also gaining traction across Europe. Solutions that demonstrate clinical effectiveness and regulatory compliance, particularly those certified as medical devices, are more likely to achieve reimbursement coverage and large-scale patient access through insurers and public healthcare systems.
Founder / Investor Commentary
Armira Growth highlighted the strategic relevance of digital neurorehabilitation, noting that technology-driven solutions can significantly improve therapy outcomes, particularly in speech and cognitive recovery. The investor emphasized that nyra health’s platform connects the entire care chain for the first time, from inpatient treatment to outpatient aftercare and home-based rehabilitation, supported by strong clinical validation and deep integration into existing care structures.
CEO and co-founder Moritz Schöllauf stated that the company’s long-term objective is to make effective, individualized neurotherapy broadly accessible, regardless of geographic location or healthcare system limitations. He noted that the new funding represents a step toward expanding access to structured rehabilitation for patients recovering from stroke and other neurological conditions.
Growth Plans / Use Of Funds
The €20 million investment will be allocated toward expanding market penetration in the DACH region, onboarding additional clinic networks, and strengthening reimbursement integrations in Germany, Austria, and Switzerland. nyra health is also preparing for entry into the US market, including collaboration with an international pharmaceutical partner to support its planned launch.
In parallel, the company will invest in the continued development of its multimodal AI models, focusing on therapeutic interaction, diagnostics, and adaptive treatment optimisation. These advancements are being supported through a €4.2 million research initiative conducted in collaboration with leading research universities in the United States.
Currently, the myReha platform is used in more than 100 neurological clinics and is integrated into the standard care framework of the German Pension Insurance (DRV). The solution is automatically reimbursed by over 28 statutory and private health insurers, providing access to structured, AI-based home therapy for more than 40 million insured individuals. Clinical studies, including randomized controlled trials, have shown that the additional use of the platform leads to significantly improved cognitive and language outcomes compared to standard therapy alone.
About nyra health
nyra health is a Vienna-based digital health company developing AI-powered platforms for neurological rehabilitation. Founded by an interdisciplinary team with expertise in neurology, machine learning, and regulatory affairs. The company’s platform includes the CE-certified therapy software myReha and the clinical management system nyra insights, enabling continuous, data-driven neurotherapy across inpatient, outpatient, and home care settings.
